Selected publications 2013–2019


ColPortal, an integrative multiomic platform for analysing epigenetic interactions in colorectal cancer.

Esteban-Gil A, Pérez-Sanz F, García-Solano J, Alburquerque-González B, Parreño-González MA, Legaz-García MDC, Fernández-Breis JT, Rodriguez-Braun E, Pimentel P, Tuomisto A, Mäkinen M, Slaby O, Conesa-Zamora P.

Sci Data. 2019 Oct 31;6(1):255. doi: 10.1038/s41597-019-0198-z.

Molecular Links between Central Obesity and Breast Cancer.

Zimta AA, Tigu AB, Muntean M, Cenariu D, Slaby O, Berindan-Neagoe I.

Int J Mol Sci. 2019 Oct 28;20(21). pii: E5364. doi: 10.3390/ijms20215364. Review.

A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.

Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, Rusu A, Irimie A, Atanasov AG, Slaby O, Ionescu C, Berindan-Neagoe I.

Cancers (Basel). 2019 Oct 22;11(10). pii: E1618. doi: 10.3390/cancers11101618. Review.

Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma.

Barth DA, Slaby O, Klec C, Juracek J, Drula R, Calin GA, Pichler M.

Cancers (Basel). 2019 Oct 17;11(10). pii: E1580. doi: 10.3390/cancers11101580. Review.

Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors.

Kopkova A, Sana J, Machackova T, Vecera M, Radova L, Trachtova K, Vybihal V, Smrcka M, Kazda T, Slaby O, Fadrus P.

Cancers (Basel). 2019 Oct 12;11(10). pii: E1546. doi: 10.3390/cancers11101546.

Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer.

Machackova T, Prochazka V, Kala Z, Slaby O.

Cancers (Basel). 2019 Oct 12;11(10). pii: E1545. doi: 10.3390/cancers11101545. Review.

MicroRNA Biogenesis Pathway Genes Are Deregulated in Colorectal Cancer.

Vychytilova-Faltejskova P, Svobodova Kovarikova A, Grolich T, Prochazka V, Slaba K, Machackova T, Halamkova J, Svoboda M, Kala Z, Kiss I, Slaby O.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4460. doi: 10.3390/ijms20184460.

MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients.

Kovacova J, Juracek J, Poprach A, Kopecky J, Fiala O, Svoboda M, Fabian P, Radova L, Brabec P, Buchler T, Slaby O.

Cancer Genomics Proteomics. 2019 Sep-Oct;16(5):353-359. doi: 10.21873/cgp.20140.

A review of microscopy-based evidence for the association of Propionibacterium acnes biofilms in degenerative disc disease and other diseased human tissue.

Capoor MN, Birkenmaier C, Wang JC, McDowell A, Ahmed FS, Brüggemann H, Coscia E, Davies DG, Ohrt-Nissen S, Raz A, Ruzicka F, Schmitz JE, Fischetti VA, Slaby O.

Eur Spine J. 2019 Jul 29. doi: 10.1007/s00586-019-06086-y. [Epub ahead of print] Review.

Identification of microRNA signatures in umbilical cord blood associated with maternal characteristics.

Juracek J, Piler P, Janku P, Radova L, Slaby O.

PeerJ. 2019 May 30;7:e6981. doi: 10.7717/peerj.6981. eCollection 2019.

MicroRNA-215: From biology to theranostic applications.

Vychytilova-Faltejskova P, Slaby O.

Mol Aspects Med. 2019 Mar 26. pii: S0098-2997(19)30001-9. doi: 10.1016/j.mam.2019.03.002. [Epub ahead of print]

MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy.

Ahmad P, Sana J, Slavik M, Gurin D, Radova L, Gablo NA, Kazda T, Smilek P, Horakova Z, Gal B, Hermanova M, Slampa P, Slaby O.

Cancer Genomics Proteomics. 2019 Mar-Apr;16(2):139-146. doi: 10.21873/cgp.20119.

Testing of library preparation methods for transcriptome sequencing of real life glioblastoma and brain tissue specimens: A comparative study with special focus on long non-coding RNAs.

Vecera M, Sana J, Oppelt J, Tichy B, Alena K, Lipina R, Smrcka M, Jancalek R, Hermanova M, Kren L, Slaby O.

PLoS One. 2019 Feb 11;14(2):e0211978. doi: 10.1371/journal.pone.0211978. eCollection 2019. PMID: 30742682


MicroRNA isolation and quantification in cerebrospinal fluid: A comparative methodical study.

Kopkova A, Sana J, Fadrus P, Machackova T, Vecera M, Vybihal V, Juracek J, Vychytilova-Faltejskova P, Smrcka M, Slaby O.

PLoS One. 2018 Dec 7;13(12):e0208580. doi: 10.1371/journal.pone.0208580. eCollection 2018. PMID: 30532175

Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.

Juracek J, Stanik M, Vesela P, Radova L, Dolezel J, Svoboda M, Slaby O.

Urol Oncol. 2018 Nov 13. pii: S1078-1439(18)30397-1. doi: 10.1016/j.urolonc.2018.10.014. [Epub ahead of print] PMID: 30446443

Prognostic impact of combined immunoprofiles in oropharyngeal squamous cell carcinoma patients with respect to AJCC 8th edition.

Gurin D, Slavik M, Hermanova M, Shatokhina T, Sana J, Kazda T, Selingerova I, Ahmad P, Smilek P, Horakova Z, Hendrych M, Slampa P, Slaby O.

J Oral Pathol Med. 2018 Oct;47(9):864-872. doi: 10.1111/jop.12772. Epub 2018 Aug 25. PMID: 30079604

Long Non-Coding RNAs in Gliomas: From Molecular Pathology to Diagnostic Biomarkers and Therapeutic Targets.

Vecera M, Sana J, Lipina R, Smrcka M, Slaby O.

Int J Mol Sci. 2018 Sep 13;19(9). pii: E2754. doi: 10.3390/ijms19092754. Review. PMID: 30217088

Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis.

Sramek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, Noskova H, Sterba J, Veselska R.

Int J Mol Sci. 2018 Sep 1;19(9). pii: E2599. doi: 10.3390/ijms19092599. PMID: 30200486

Is IL-1β Further Evidence for the Role of Propionibacterium acnes in Degenerative Disc Disease? Lessons From the Study of the Inflammatory Skin Condition Acne Vulgaris.

Slaby O, McDowell A, Brüggemann H, Raz A, Demir-Deviren S, Freemont T, Lambert P, Capoor MN.

Front Cell Infect Microbiol. 2018 Aug 14;8:272. doi: 10.3389/fcimb.2018.00272. eCollection 2018. PMID: 30155445

Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?

Kazda T, Dziacky A, Burkon P, Pospisil P, Slavik M, Rehak Z, Jancalek R, Slampa P, Slaby O, Lakomy R.

Radiol Oncol. 2018 Jun 6;52(2):121-128. doi: 10.2478/raon-2018-0023. eCollection 2018 Jun. Review. PMID: 30018514

Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.

Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.

Cancer Genomics Proteomics. 2018 Jul-Aug;15(4):321-327. doi: 10.21873/cgp.20090. PMID: 29976637

Tumor Expression of miR-10b, miR-21, miR-143 and miR-145 Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population.

Obermannova R, Redova-Lojova M, Vychytilova-Faltejskova P, Grell P, Cho WC, Sachlova M, Svoboda M, Vyzula R, Slaby O.

Anticancer Res. 2018 Jun;38(6):3719-3724. doi: 10.21873/anticanres.12651. PMID: 29848733

MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.

Kovacova J, Poprach A, Buchler T, Cho WC, Slaby O.

Clin Chem Lab Med. 2018 Feb 16. pii: /j/cclm.ahead-of-print/cclm-2017-0861/cclm-2017-0861.xml. doi: 10.1515/cclm-2017-0861. Review. PMID: 29451857

Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors.

Kopkova A, Sana J, Fadrus P, Slaby O.

Clin Chem Lab Med. 2018 Feb 16. pii: /j/cclm.ahead-of-print/cclm-2017-0958/cclm-2017-0958.xml. doi: 10.1515/cclm-2017-0958. Review. PMID: 29451858

Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival.

Sana J, Busek P, Fadrus P, Besse A, Radova L, Vecera M, Reguli S, Stollinova Sromova L, Hilser M, Lipina R, Lakomy R, Kren L, Smrcka M, Sedo A, Slaby O.

Scientific Reports. 2018 Feb 12;8(1):2836.

Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.

Juracek J, Peltanova B, Dolezel J, Fedorko M, Pacik D, Radova L, Vesela P, Svoboda M, Slaby O, Stanik M. 

J Cell Mol Med. 2018 Jan 24. doi: 10.1111/jcmm.13487.

Exercise-induced circulating microRNA changes in athletes in various training scenarios.

Horak M, Zlamal F, Iliev R, Kucera J, Cacek J, Svobodova L, Hlavonova Z, Kalina T, Slaby O, Bienertova-Vasku J. 

PLoS One. 2018 Jan 16;13(1):e0191060.


Therapeutic targeting of non-coding RNAs in cancer.

Slaby O, Laga R, Sedlacek O. 

Biochem J. 2017 Dec 14;474(24):4219-4251. doi: 10.1042/BCJ20170079. Review. PubMed PMID: 29242381.

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9.

Vychytilova-Faltejskova P, Merhautova J, Machackova T, Gutierrez-Garcia I, Garcia-Solano J, Radova L, Brchnelova D, Slaba K, Svoboda M, Halamkova J, Demlova R, Kiss I, Vyzula R, Conesa-Zamora P, Slaby O. 

Oncogenesis. 2017 Dec 4;6(11):399.

Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.

Abt D, Besse A, Sedlarikova L, Kraus M, Bader J, Silzle T, Vodinska M, Slaby O, Schmid HP, Engeler DS, Driessen C, Besse L. 

BJU Int. 2017 Nov 21. doi: 10.1111/bju.14083.

A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.

Valianatos G, Valcikova B, Growkova K, Verlande A, Mlcochova J, Radova L, Stetkova M, Vyhnakova M, Slaby O, Uldrijan S.

PLoS One. 2017 Oct 3;12(10):e0185801. doi: 10.1371/journal.pone.0185801

Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma.

Fedorko M, Juracek J, Stanik M, Svoboda M, Poprach A, Buchler T, Pacik D, Dolezel J, Slaby O.

Biochem Med (Zagreb). 2017 Jun 15;27(2):411-417. doi: 10.11613/BM.2017.043.

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX.

Kiss I, Mlčochová J, Součková K, Fabian P, Poprach A, Halamkova J, Svoboda M, Vyzula R, Slaby O.

Oncol Lett. 2017 Jul;14(1):743-750. doi: 10.3892/ol.2017.6255.

MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.

Goblirsch M, Richtig G, Slaby O, Berindan-Neagoe I, Gerger A, Pichler M.

Pharmacogenomics. 2017 Jul;18(10):1027-1038.

miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.

Stiegelbauer V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, Reicher A, Resel M, Heitzer E, Ivan C, Bullock M, Ling H, Deutsch A, Wulf-Goldenberg A, Adiprasito JB, Stoeger H, Haybaeck J, Svoboda M, Stotz M, Hoefler G, Slaby O, Calin GA, Gerger A, Pichler M.

Clin Cancer Res. 2017 Sep 1;23(17):5255-5266. doi: 10.1158/1078-0432.CCR-17-0023.

MicroRNAs Involvement in Radioresistance of Head and Neck Cancer.

Ahmad P, Sana J, Slavik M, Slampa P, Smilek P, Slaby O.

Dis Markers. 2017;2017:8245345. doi: 10.1155/2017/8245345

Propionibacterium acnes biofilm is present in intervertebral discs of patients undergoing microdiscectomy.

Capoor MN, Ruzicka F, Schmitz JE, James GA, Machackova T, Jancalek R, Smrcka M, Lipina R, Ahmed FS, Alamin TF, Anand N, Baird JC, Bhatia N, Demir-Deviren S, Eastlack RK, Fisher S, Garfin SR, Gogia JS, Gokaslan ZL, Kuo CC, Lee YP, Mavrommatis K, Michu E, Noskova H, Raz A, Sana J, Shamie AN, Stewart PS, Stonemetz JL, Wang JC, Witham TF, Coscia MF, Birkenmaier C, Fischetti VA, Slaby O.

PLoS One. 2017 Apr 3;12(4):e0174518. doi: 10.1371/journal.pone.0174518.

Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells.

Ondracek J, Fadrus P, Sana J, Besse A, Loja T, Vecera M, Radova L, Smrcka M, Slampa P, Slaby O.

Anticancer Res. 2017 Mar;37(3):1099-1104.

Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene.

Mudry P, Slaby O, Neradil J, Soukalova J, Melicharkova K, Rohleder O, Jezova M, Seehofnerova A, Michu E, Veselska R, Sterba J.

BMC Cancer. 2017 Feb 10;17(1):119. doi: 10.1186/s12885-017-3115-x.

Doxorubicin and Liposomal Doxorubicin Differentially Affect Expression of miR-208a and let-7g in Rat Ventricles and Atria.

Novak J, Sana J, Stracina T, Novakova M, Slaby O.

Cardiovasc Toxicol. 2017 Jul;17(3):355-359. doi: 10.1007/s12012-016-9393-8.


Systemic administration of miRNA mimics by liposomal delivery system in animal model of colorectal carcinoma.

Merhautová J, Vychytilová-Faltejsková P, Demlová R, Slabý O.

Physiol Res. 2016 Dec 21;65(Supplementum 4):S481-S488.

Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma.

Iliev R, Fedorko M, Machackova T, Mlcochova H, Svoboda M, Pacik D, Dolezel J, Stanik M, Slaby O.

Anticancer Res. 2016 Dec;36(12):6419-6423.

H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer.

Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, Ajani JA, Radovich M, Calin GA.

EBioMedicine. 2016 Nov;13:113-124. doi: 10.1016/j.ebiom.2016.10.026. 

MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers.

Merhautova J, Demlova R, Slaby O.

Front Pharmacol. 2016 Sep 27;7:329.

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.

Kiss I, Mlcochova J, Bortlicek Z, Poprach A, Drabek J, Vychytilova-Faltejskova P, Svoboda M, Buchler T, Batko S, Ryska A, Hajduch M, Slaby O.

Anticancer Res. 2016 Sep;36(9):4955-9.

MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition.

Machackova T, Mlcochova H, Stanik M, Dolezel J, Fedorko M, Pacik D, Poprach A, Svoboda M, Slaby O.

Tumour Biol. 2016 Nov;37(11):14653-14658

Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.

Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, Ling H, Winter E, Zhang X, Goblirsch M, Wulf-Goldenberg A, Ohtsuka M, Haybaeck J, Svoboda M, Okugawa Y, Gerger A, Hoefler G, Goel A, Slaby O, Calin GA.

Clin Cancer Res. 2017 Mar 1;23(5):1323-1333. doi: 10.1158/1078-0432.CCR-16-0497.

Non-coding RNAs as Biomarkers for Colorectal Cancer Screening and Early Detection.

Slaby O.

Adv Exp Med Biol. 2016;937:153-70. doi: 10.1007/978-3-319-42059-2_8. 

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.

Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, Slaby O, Svoboda M.

Onco Targets Ther. 2016 Jul 28;9:4695-703. doi: 10.2147/OTT.S102891.

Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma.

Mlcochova H, Machackova T, Rabien A, Radova L, Fabian P, Iliev R, Slaba K, Poprach A, Kilic E, Stanik M, Redova-Lojova M, Svoboda M, Dolezel J, Vyzula R, Jung K, Slaby O.

Sci Rep. 2016 Aug 23;6:31852. doi: 10.1038/srep31852.

Prevalence of Propionibacterium acnes in Intervertebral Discs of Patients Undergoing Lumbar Microdiscectomy: A Prospective Cross-Sectional Study.

Capoor MN, Ruzicka F, Machackova T, Jancalek R, Smrcka M, Schmitz JE, Hermanova M, Sana J, Michu E, Baird JC, Ahmed FS, Maca K, Lipina R, Alamin TF, Coscia MF, Stonemetz JL, Witham T, Ehrlich GD, Gokaslan ZL, Mavrommatis K, Birkenmaier C, Fischetti VA, Slaby O.

PLoS One. 2016 Aug 18;11(8):e0161676. doi: 10.1371/journal.pone.0161676. eCollection 2016.

Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer.

Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M, Kiss I, Vyzula R, Slaby O.

Carcinogenesis. 2016 Oct;37(10):941-950. doi: 10.1093/carcin/bgw078. Epub 2016 Aug 1.

Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.

Iliev R, Kleinova R, Juracek J, Dolezel J, Ozanova Z, Fedorko M, Pacik D, Svoboda M, Stanik M, Slaby O.

Tumour Biol. 2016 Oct;37(10):13385-13390. Epub 2016 Jul 27.

Genome-wide microRNA Expression Profiling in Primary Tumors and Matched Liver Metastasis of Patients with Colorectal Cancer.

Vychytilova-Faltejskova P, Pesta M, Radova L, Liska V, Daum O, Kala Z, Svoboda M, Kiss I, Slaby O.

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):311-6.

Future paradigms for precision oncology.

Klement GL, Arkun K, Valik D, Roffidal T, Hashemi A, Klement C, Carmassi P, Rietman E, Slaby O, Mazanek P, Mudry P, Kovacs G, Kiss C, Norga K, Konstantinov D, André N, Slavc I, van Den Berg H, Kolenova A, Kren L, Tuma J, Skotakova J, Sterba J.

Oncotarget. 2016 Jul 19;7(29):46813-46831. doi: 10.18632/oncotarget.9488. Review.

Decreased expression levels of PIWIL1, PIWIL2, and PIWIL4 are associated with worse survival in renal cell carcinoma patients.

Iliev R, Stanik M, Fedorko M, Poprach A, Vychytilova-Faltejskova P, Slaba K, Svoboda M, Fabian P, Pacik D, Dolezel J, Slaby O.

Onco Targets Ther. 2016 Jan 8;9:217-22. doi: 10.2147/OTT.S91295. eCollection 2016.

MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.

Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Sachlova M, Svoboda M, Slaby O.

Tumour Biol. 2016 Jun;37(6):8007-18. doi: 10.1007/s13277-015-4656-8. Epub 2015 Dec 28.

MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.

Besse A, Sana J, Lakomy R, Kren L, Fadrus P, Smrcka M, Hermanova M, Jancalek R, Reguli S, Lipina R, Svoboda M, Slampa P, Slaby O.

Tumour Biol. 2016 Jun;37(6):7719-27. doi: 10.1007/s13277-015-4654-x. Epub 2015 Dec 21.


Circulating Blood-Borne microRNAs as Biomarkers in Solid Tumors.

Vychytilova-Faltejskova P, Slaby O.

EXS. 2015;106:75-122. doi: 10.1007/978-3-0348-0955-9_4.

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, Negrini M.

BMC Cancer. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5.

Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer.

Thorenoor N, Faltejskova-Vychytilova P, Hombach S, Mlcochova J, Kretz M, Svoboda M, Slaby O.

Oncotarget. 2016 Jan 5;7(1):622-37. doi: 10.18632/oncotarget.5807.

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.

Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss I, Vyzula R, Negrini M, Slaby O.

Oncotarget. 2015 Nov 17;6(36):38695-704. doi: 10.18632/oncotarget.5735.

Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.

Fedorko M, Stanik M, Iliev R, Redova-Lojova M, Machackova T, Svoboda M, Pacik D, Dolezel J, Slaby O.

Int J Mol Sci. 2015 Sep 29;16(10):23382-9. doi: 10.3390/ijms161023382.

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R.

PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. eCollection 2015.

Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes.

Machal J, Novak J, Hezova R, Zlamal F, Vasku A, Slaby O, Bienertova-Vasku J.

Genes Nutr. 2015 Sep;10(5):488. doi: 10.1007/s12263-015-0488-9. Epub 2015 Aug 26.

miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib.

Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R, Slaby O.

Biomed Res Int. 2015;2015:941980. doi: 10.1155/2015/941980. Epub 2015 May 3.

Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus.

Hezova R, Kovarikova A, Srovnal J, Zemanova M, Harustiak T, Ehrmann J, Hajduch M, Svoboda M, Sachlova M, Slaby O.

Diagn Pathol. 2015 Apr 28;10:42. doi: 10.1186/s13000-015-0280-6.

MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma.

Vychytilova-Faltejskova P, Kiss I, Klusova S, Hlavsa J, Prochazka V, Kala Z, Mazanec J, Hausnerova J, Kren L, Hermanova M, Lenz J, Karasek P, Vyzula R, Slaby O.

Diagn Pathol. 2015 Apr 24;10:38. doi: 10.1186/s13000-015-0272-6.

Dynamic changes in microRNA expression profiles reflect progression of Barrett's esophagus to esophageal adenocarcinoma.

Slaby O, Srovnal J, Radova L, Gregar J, Juracek J, Luzna P, Svoboda M, Hajduch M, Ehrmann J.

Carcinogenesis. 2015 May;36(5):521-7. doi: 10.1093/carcin/bgv023. Epub 2015 Mar 16.

Small nucleolar RNAs functioning and potential roles in cancer.

Thorenoor N, Slaby O.

Tumour Biol. 2015 Jan;36(1):41-53. doi: 10.1007/s13277-014-2818-8. Epub 2014 Nov 25. Review.

Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.

Sana J, Radova L, Lakomy R, Kren L, Fadrus P, Smrcka M, Besse A, Nekvindova J, Hermanova M, Jancalek R, Svoboda M, Hajduch M, Slampa P, Vyzula R, Slaby O.

Carcinogenesis. 2014 Dec;35(12):2756-62. doi: 10.1093/carcin/bgu212. Epub 2014 Oct 16.

Urinary microRNAs as a new class of noninvasive biomarkers in oncology, nephrology, and cardiology.

Mlcochova H, Hezova R, Meli AC, Slaby O.

Methods Mol Biol. 2015;1218:439-63. doi: 10.1007/978-1-4939-1538-5_26. Review.


MicroRNA profiling of activated and tolerogenic human dendritic cells.

Stumpfova Z, Hezova R, Meli AC, Slaby O, Michalek J.

Mediators Inflamm. 2014;2014:259689. doi: 10.1155/2014/259689. Epub 2014 Apr 1.

MicroRNA-206: a promising theranostic marker.

Novák J, Kružliak P, Bienertová-Vašků J, Slabý O, Novák M.

Theranostics. 2014 Jan 2;4(2):119-33. doi: 10.7150/thno.7552. eCollection 2014. Review.

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.

Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R.

Haematologica. 2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500. Epub 2013 Nov 15.

Urine microRNAs as potential noninvasive biomarkers in urologic cancers.

Mlcochova H, Hezova R, Stanik M, Slaby O.

Urol Oncol. 2014 Jan;32(1):41.e1-9. doi: 10.1016/j.urolonc.2013.04.011. Epub 2013 Sep 10. Review.


MicroRNAs targeting EGFR signalling pathway in colorectal cancer.

Mlcochova J, Faltejskova P, Nemecek R, Svoboda M, Slaby O.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1615-24. doi: 10.1007/s00432-013-1470-9. Epub 2013 Jul 2. Review.

MicroRNAs involved in skeletal muscle development and their roles in rhabdomyosarcoma pathogenesis.

Novák J, Vinklárek J, Bienertová-Vašků J, Slabý O.

Pediatr Blood Cancer. 2013 Nov;60(11):1739-46. doi: 10.1002/pbc.24664. Epub 2013 Jun 27. Review. Erratum in: Pediatr Blood Cancer. 2014 Feb;61(2):390.

Extension of microRNA expression pattern associated with high-risk neuroblastoma.

Bienertova-Vasku J, Mazanek P, Hezova R, Curdova A, Nekvindova J, Kren L, Sterba J, Slaby O.

Tumour Biol. 2013 Aug;34(4):2315-9. doi: 10.1007/s13277-013-0777-0. Epub 2013 Jun 20.

The role of microRNAs in mitochondria in cancer.

Bienertova-Vasku J, Sana J, Slaby O.

Cancer Lett. 2013 Aug 9;336(1):1-7. doi: 10.1016/j.canlet.2013.05.001. Epub 2013 May 9. Review.

MicroRNAs involved in chemo- and radioresistance of high-grade gliomas.

Besse A, Sana J, Fadrus P, Slaby O.

Tumour Biol. 2013 Aug;34(4):1969-78. doi: 10.1007/s13277-013-0772-5. Epub 2013 Apr 9. Review.

Circulating miRNAs as new blood-based biomarkers for solid cancers.

Redova M, Sana J, Slaby O.

Future Oncol. 2013 Mar;9(3):387-402. doi: 10.2217/fon.12.192. Review.

Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer.

Slaby O, Sachlova M, Brezkova V, Hezova R, Kovarikova A, Bischofová S, Sevcikova S, Bienertova-Vasku J, Vasku A, Svoboda M, Vyzula R.

Nutr Cancer. 2013;65(2):247-54. doi: 10.1080/01635581.2013.756530.

MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.

Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, Radova L, Svoboda M, Dolezel J, Vyzula R, Slaby O.

Tumour Biol. 2013 Feb;34(1):481-91. doi: 10.1007/s13277-012-0573-2. Epub 2012 Nov 13.

Serum miR-29a as a marker of multiple myeloma.

Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R.

Leuk Lymphoma. 2013 Jan;54(1):189-91. doi: 10.3109/10428194.2012.704030. Epub 2012 Aug 14. No abstract available